Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$2.19 USD
-0.01 (-0.45%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $2.20 +0.01 (0.46%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Brokerage Reports
Cellectar Biosciences, Inc. [CLRB]
Reports for Purchase
Showing records 61 - 80 ( 126 total )
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Near-Cash Valuation Completely Unwarranted, Signs Manufacturing Partner
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Eyes on CLOVER-WaM Interim Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
2Q21: Pivotal CLR 131 Results in 3Q22, Sufficiently Funded Into 2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Expands Existing Drug Linker/Payload Collaboration with IntoCell
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Signs Drug Development/Commercialization Collaboration with LegoChem Bio
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Positive Clinical Update From CLOVER-1 Bodes Well For CLOVER-WaM
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Phase 2a Results Show Consistent CLR 131 Efficacy in Refractory LPL/WM
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
WM Pivotal Study Advancing; IP Strengthened; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
1Q21: Pivotal WM Trial Results Likely in 3Q22, Well-Funded for Two Years
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Strengthens PDC Technology IP Estate; CLR 131 Pivotal Trial Progressing
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Healthcare- Annual ROTH Conference: Cancer Panel Takeaways
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cellectar Biosciences, Inc.
Industry: Medical - Products
Pivotal Study in WM Initiated; Clinical Updates in 2021 Could Provide Inflection; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S